PSC
ELGX

Piper Sandler & Co’s Endologix Inc ELGX Stock Holding History

Piper Sandler & Co’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,000
Closed -$129K – 158
2014
Q1 		$129K Buy
+1,000
New +$155K 0.11% 86

Other funds holding ELGX

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Piper Sandler & Co's ELGX Position: Q2 2014 in Review

Piper Sandler & Co sold out of Endologix Inc (ELGX) in Q2 2014, closing a stake of 1,000 shares — an estimated $129K sold.

Piper Sandler & Co first reported a position in ELGX in Q1 2014 and held it in 1 quarter. The position peaked at $129K in Q1 2014. 119 funds tracked by Wall St. Rank hold ELGX as of Q2 2014.

  • Piper Sandler & Co reported no remaining Endologix Inc position as of Q2 2014 after selling out during the quarter.
  • Piper Sandler & Co sold 1,000 Endologix Inc shares in Q2 2014, an estimated $129K.
  • Piper Sandler & Co first reported a position in Endologix Inc in Q1 2014 and held it in 1 quarter.
  • Piper Sandler & Co's Endologix Inc position peaked at $129K in Q1 2014.
  • 119 funds tracked by Wall St. Rank held Endologix Inc as of Q2 2014.

Based on Piper Sandler & Co's 13F filing for Q2 2014, filed 14 Aug 2014.